Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM347TQ)

Drug Name

MK-3697 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Orexin receptor type 2 (HCRTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Suvorexant	DM0E6S3	Insomnia	7A00-7A0Z	Approved	[3]
MIN-202	DMZFW8V	Major depressive disorder	6A70.3	Phase 2	[4]
TAK-861	DMLGEQ7	Narcolepsy type 1	7A20.0	Phase 2	[5]
TAK-925	DM7N4H9	Narcolepsy	7A20	Phase 1	[6]
1,2-diamino cyclopentane-based derivative 25	DMEW0AT	N. A.	N. A.	Patented	[7]
1,2-diamino cyclopentane-based derivative 5	DMCP15K	N. A.	N. A.	Patented	[7]
1,2-diamino cyclopentane-based derivative 20	DM9PHIK	N. A.	N. A.	Patented	[7]
1,2-diamino cyclopentane-based derivative 15	DMBY65W	N. A.	N. A.	Patented	[7]
1,2-diamino cyclopentane-based derivative 13	DM10UX4	N. A.	N. A.	Patented	[7]
1,2-diamino cyclopentane-based derivative 9	DM7I8ZV	N. A.	N. A.	Patented	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033199)
2	Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90.
3	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
6	Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022 May 25;13(1):2902.
7	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.